Tissue slice grafts of human renal cell carcinoma: An authentic preclinical model with high engraftment rate and metastatic potential

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 43.e23-43.e30

  Thong, Alan E ^a   Zhao, Hongjuan ^a   Ingels, Alexandre ^a,b   Valta, Maija P ^a,c   Nolley, Rosalie ^a   Santos, Jennifer ^a   Young, Sarah R ^a   Peehl, Donna M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BICÊTRE HOSPITAL   (France)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Metastases; Renal cancer; Tumorgrafts

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 7; KU ANTIGEN; STEM CELL FACTOR RECEPTOR; SUNITINIB; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MONITORING; BONE METASTASIS; CANCER CELL; CANCER GRAFT; CANCER GROWTH; CANCER MODEL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CAPSULE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; ORGAN WEIGHT; PANCREAS METASTASIS; PRIORITY JOURNAL; TISSUE SLICE; TUMOR ENGRAFTMENT; TUMOR VOLUME;

METASTASES; RENAL CANCER; TUMORGRAFTS;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION PROFILING; GRAFT SURVIVAL; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; PYRROLES; SEQUENCE HOMOLOGY, AMINO ACID; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890787865     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.05.008     Document Type: Article

References (19)

1. Dennis C. Mouse avatars couldaidpancreaticcancertherapy. Nature News 2012. http://dx.doi.org/10.1038/nature.2012.10259.
2. DeRose Y.S., Wang G., Lin Y.C., Bernard P.S., Buys S.S., Ebbert M.T., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011, 17:1514-1520.
3. Garber K. Personal mouse colonies give hope for pancreatic cancer patients. J Natl Cancer Inst 2007, 99:105-107.
4. Garber K. From human to mouse and back: tumorgraft models surge in popularity. J Natl Cancer Inst 2009, 101:6-8.
5. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., Garrido-Laguna I., De Oliveira E., Rubio-Viqueira B., et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011, 10:1311-1316.
6. Karam J.A., Zhang X.Y., Tamboli P., Margulis V., Wang H., Abel E.J., et al. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol 2011, 59:619-628.
7. Sivanand S., Pena-Llopis S., Zhao H., Kucejova B., Spence P., Pavia-Jimenez A., et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med 2012, 4. 137ra75.
8. Grisanzio C., Seeley A., Chang M., Collins M., Di Napoli A., Cheng S.C., et al. Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol 2011, 225:212-221.
9. Fisher R., Larkin J., Swanton C. Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma?. Front Oncol 2012, 2:49.
10. Zhao H., Nolley R., Chen Z., Peehl D.M. Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol 2010, 177:229-239.
11. Wood L. Sunitinib malate for the treatment of renal cell carcinoma. Expert Opin Pharmacother 2012, 13:1323-1336.
12. van Rijn R.S., Simonetti E.R., Hagenbeek A., Hogenes M.C., de Weger R.A., Canninga-van Dijk M.R., et al. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 2003, 102:2522-2531.
13. Al-Ahmadie H.A., Alden D., Fine S.W., Gopalan A., Touijer K.A., Russo P., et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol 2011, 35:949-961.
14. Jones S., Chen W., Parmigiani G., Diehl F., Beerenwinkel N., Antal A., et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci 2008, 105:4283-4288.
15. Harraz M., Jiao C., Hanlon H.D., Hartley R.S., Schatteman G.C. CD34- blood-derived human endothelial cell progenitors. Stem Cells 2001, 19:304-312.
16. Wood S.L., Brown J.E. Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 2012, 38:284-291.
17. Beuselinck B., Wolter P., Karadimou A., Elaidi R., Dumez H., Rogiers A., et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 2012, 107:1665-1671.
18. Figlin R., Sternberg C., Wood C.G. Novel agents and approaches for advanced renal cell carcinoma. J Urol 2012, 188:707-715.
19. Pal S.K., Williams S., Josephson D.Y., Carmichael C., Vogelzang N.J., Quinn D.I. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther 2012, 11:526-537.